Standardized maqui berry extract supports eye dryness, says recent study

May 28, 2019

A recent study published in the Journal of Traditional and Complementary Medicine1 found that a standardized maqui berry extract (MaquiBright by MNL Group; Santiago Chile) relieved symptoms of dry eyes.

A recent study published in the Journal of Traditional and Complementary Medicine1 found that a standardized maqui berry extract (MaquiBright by MNL Group; Santiago Chile) relieved symptoms of dry eyes. In the study, 74 subjects between the ages of 30- and 60-years experiencing eye dryness, eye fatigue, and more than four hours working at a visual display terminal daily, were randomly assigned to receive 60 mg of MaquiBright or placebo every day for four weeks.

Results showed that subjects taking the maqui berry extract had a significantly higher production of lacrimal fluid when eye dryness was measured, and for subjective symptoms reported significantly higher reductions in eye fatigue compared to placebo. The increase in lacrimal fluid may be stimulated by delphinidin-3,5-O-diglucoside found in MaquiBright, write the researchers, which is a compound known to inhibit the production of reactive oxygen species in lacrimal gland tissue, and known to suppress corneal damage as well as lacrimal gland tissue dysfunction, preventing eye dryness.

The ingredient is distributed by Charles Bowman and Company (Holland, MI).

References:

1. S. Yamashita et al. “Effects of MaquiBright® on improving eye dryness and fatigue in humans: A randomized, double-blind, placebo-controlled trial.” Journal of Traditional and Complementary Medicine, Published ahead of print on November 22, 2018